导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.39% | 1653/4773 |
| 近一周 | -2.42% | 2116/5462 |
| 近一月 | -7.91% | 4030/5421 |
| 近一季 | 12.47% | 108/5209 |
| 近半年 | 4.60% | 820/4920 |
| 近一年 | -9.21% | 3309/4366 |
| 近两年 | 36.55% | 2035/2954 |
| 近三年 | 6.35% | 1815/2253 |
| 成立以来 | 82.14% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.73% 1929/4961 |
-1.77% 3366/5312 |
- - |
- - |
| 2025 | 14.59% 2599/4813 |
3.28% 1133/3635 |
3.92% 912/4076 |
20.28% 2001/4524 |
-11.23% 4194/4813 |
| 2024 | -10.06% 2337/3463 |
-12.72% 2464/2808 |
-8.73% 2277/3014 |
21.26% 601/3129 |
-6.90% 2714/3463 |
| 2023 | -6.03% 803/2656 |
0.20% 1748/2280 |
-5.90% 1556/2385 |
2.24% 242/2515 |
-2.53% 489/2655 |
| 2022 | -22.99% 1105/2207 |
-10.80% 427/1919 |
-2.60% 1781/2016 |
-19.32% 1771/2113 |
9.86% 192/2208 |
| 2021 | -2.12% 836/1822 |
-2.10% 582/1255 |
12.81% 307/1330 |
-9.48% 1180/1466 |
-2.10% 1400/1822 |
| 2020 | 58.63% 135/1250 |
7.23% 37/1022 |
29.40% 76/1060 |
8.22% 719/1152 |
- - |
| 2019 | 31.74% 458/1092 |
27.68% 333/748 |
-7.38% 553/797 |
5.39% 150/844 |
5.70% 684/912 |
| 2018 | -23.44% 279/834 |
- - |
- - |
- - |
-18.35% 655/691 |
| 2017 | 22.45% 150/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.97% 272/605 |
- - |
- - |
- - |
- - |
| 2015 | 32.42% 71/575 |
- - |
- - |
- - |
- - |
| 2014 | 8.03% 216/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中信保诚中证800医药指数(LOF)A VS. 长安沪深300非周期A(740101) |